---
created: 2025-04-13
updated: 2025-04-13T10:53
id: u)/AJhxv2-
specialty: pharmaco
specialty_id: 353
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::04-cancer-drugs::01-antimetabolites
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::09-cancer-therapy-cell-cycle
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::12-antimetabolites
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::12-antimetabolites::nucleoside-analogs::cladribine
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::14-cladribine
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::cladribine
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::01-antimetabolites::03-cladribine,-cytarabine,-gemcitabine::zanki-extra
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^fa-updates::fa2019
  - source/ak-step1-v11::^other::^highyield::1-highyield"
type: flashcard
---

# Question
Cladribine is an antineoplastic purine nucleoside analog that prevents cell cycle progression at the **S*** phase

---

# Answer
*FA 2019: all antimetabolites are S-phase specific, except cladribine, which is cell cycle nonspecific (due to multiple MOAs)